Latest Breaking News On - Prostate cancer working group - Page 1 : comparemela.com

APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?

APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMemorial sloan kettering cancer centerMichael morrisSociety of urologic oncologyProstate cancer working groupUniversity of torontoInternational multicenter studyDivision of solid tumor oncologyProstate cancer consensus conferenceResponse evaluation usingMetastatic castration resistant prostate cancerMedical oncologistClinical directorGenitourinary medical oncology serviceProstate cancer section head

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoAmanda crayJohn valliantExchange commissionProstate cancer working groupFusion pharmaceuticals announces presentation of interim dataDevelopment programFusion pharmaceuticals incAmerican association for cancer researchInvestor relations corporate communicationsFusion pharmaceuticalsPharmaceuticals announces presentationInterim dataTrial evaluatingAmerican association

FDA Grants Fast Track Designation to BXCL701 for Small Cell Neuroendocrine Prostate Cancer

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

Vimal mehtaVincentj oneillProstate cancer working groupProduct developmentBioxcel therapeutics incBioxcel therapeuticsOnkosxcel therapeuticsCancers symposiumMedical officerXcel therapeuticsMetastatic small cell neuroendocrine prostate cancer

Olaparib combo improves PFS in metastatic prostate cancer

Frontline olaparib plus abiraterone/prednisone combo improves survival in patients with metastatic castration-resistant prostate cancer.

United kingdomBritish columbiaUnited statesMaha hussainKimn chiRoberth lurie comprehensive cancer centerProstate cancer working groupUniversity of british columbiaComprehensive cancer centerBoth dr hussainProstate carcinomaAlignant prostate neoplasmProstate cancerAncer of the prostateBreast cancerAlignant breast neoplasm

Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI

Men with metastatic castration-resistant prostate cancer had a slight but significant improvement in progression-free survival with a TKI plus immunotherapy vs hormonal therapy.

United statesUniversity of utahUnited kingdomSalt lake cityBritish columbiaKimn chiNeeraj agarwalKim chiXin gaoProstate cancer working groupUniversity of british columbiaCancer centerHuntsman cancer instituteSalt lakeMass general cancer centerProstate carcinoma